Radiolabelling methods
AssigneeHammersmith Imanet Limited
InventorsMatthias Eberhard Glaser, Erik Arstad
Life of this patent
Estimating the term…
Abstract
The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C≡N+—O− (II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.
Claims3
A method of monitoring the effect of treatment of a human or animal body with a drug to combat a condition associated with cancer to detecting the uptake of a compound of formula (V) or (VI):
- wherein L1, L2, L3, and L4 are each Linker groups;
- R* is a reporter moiety which comprises a radionuclide;
- and the vector is a peptide, protein, hormone, cell, bacterium, virus, or low molecular weight drug by cell receptors.
Dependencies are inferred from the claim text.